Sandoz Group AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira

Phase 3

Completed

Conditions: Plaque Type Psoriasis

Interventions: Drug: GP2017 Adalimumab
Drug: Humira ® Adalimumab

First Posted Date: 2013-12-19

Last Posted Date: 2017-05-30

Lead Sponsor: Sandoz

Target Recruit Count: 465

Registration Number: NCT02016105

Locations: 🇺🇸
Palmtree Clinical Research, Rancho Mirage, California, United States
🇺🇸
Menter Dermatology Research Institute, Dallas, Texas, United States
🇺🇸
Medical Development Centers, LLC, Baton Rouge, Louisiana, United States

and more 76 locations

GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Indolent B-cell Non-Hodgkin's Lymphoma

Interventions: Drug: GP2013

First Posted Date: 2013-09-02

Last Posted Date: 2018-07-26

Lead Sponsor: Sandoz

Target Recruit Count: 6

Registration Number: NCT01933516

Locations: 🇯🇵
Investigative Site, Tachikawa, Tokyo, Japan

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

Phase 3

Completed

Conditions: Chronic Stable Plaque Psoriasis

Interventions: Drug: GP2015 Etanercept
Drug: Enbrel

First Posted Date: 2013-07-03

Last Posted Date: 2017-03-27

Lead Sponsor: Sandoz

Target Recruit Count: 531

Registration Number: NCT01891864

Locations: 🇸🇰
Sandoz Investigational Site 2, Bratislava, Slovakia
🇷🇴
Sandoz Investigational Site 3, Bucharest, Romania
🇵🇱
Sandoz Investigational Site 4, Lodz, Poland

and more 3 locations

Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia

Phase 4

Terminated

Conditions: Severe Chronic Neutropenia

Interventions: Biological: Filgrastim

First Posted Date: 2013-05-22

Last Posted Date: 2016-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 6

Registration Number: NCT01859637

Locations: 🇩🇪
Medizinischen Hochschule (MHH) Hannover, Hannover, Germany
🇸🇪
Karolinska Institut, Stockholm, Sweden

Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors

Active, not recruiting

Conditions: Hematopoietic Stem Cell Mobilization

First Posted Date: 2013-01-11

Last Posted Date: 2024-06-10

Lead Sponsor: Sandoz

Target Recruit Count: 245

Registration Number: NCT01766934

Locations: 🇩🇪
German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen, Institute for Transfusion medicine und Immunohematology Frankfurt am Main, Frankfurt/Main, Hessen, Germany
🇩🇪
German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen, Institute for Clinical Transfusion medicine and Immunogenetics Ulm (IKT), Ulm, Germany

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®

Phase 3

Completed

Conditions: Neutropenic Complications
Breast Neoplasms
Chemotherapy-induced Neutropenia
Chemotherapeutic Toxicity

Interventions: Drug: Neulasta®
Drug: LA-EP2006

First Posted Date: 2012-11-28

Last Posted Date: 2017-08-07

Lead Sponsor: Sandoz

Target Recruit Count: 316

Registration Number: NCT01735175

Locations: 🇺🇦
Sandoz Investigational Site, Zaporizhzhia, Ukraine

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Phase 3

Completed

Conditions: Anemia
Chronic Kidney Disease (CKD)

Interventions: Drug: HX575 epoetin alfa
Drug: US-licensed epoetin alfa

First Posted Date: 2012-09-26

Last Posted Date: 2017-07-02

Lead Sponsor: Sandoz

Target Recruit Count: 435

Registration Number: NCT01693029

Locations: 🇺🇸
Pegasus Dialysis, LLC, Bakersfield, California, United States
🇺🇸
Central Nephrology Medical Group, Bakersfield, California, United States
🇺🇸
St Vincent Dialysis Center, Los Angeles, California, United States

and more 46 locations

Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa

Phase 4

Completed

Conditions: Impulse Control Disorder

Interventions: Drug: Levodopa/Carbidopa(200mg/50mg)
Drug: Dopaminergic Agonists

First Posted Date: 2012-09-11

Last Posted Date: 2021-03-10

Lead Sponsor: Sandoz

Target Recruit Count: 150

Registration Number: NCT01683253

Locations: 🇰🇷
Sandoz Investigative Site, Seoul, Korea, Republic of

Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

Phase 4

Completed

Conditions: Parkinson's Disease

Interventions: Drug: pramipexole
Drug: Bromocriptine

First Posted Date: 2012-08-28

Last Posted Date: 2017-09-15

Lead Sponsor: Sandoz

Target Recruit Count: 121

Registration Number: NCT01673724

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 4 locations

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: HX575 epoetin alfa (Sandoz)

First Posted Date: 2012-04-12

Last Posted Date: 2017-06-19

Lead Sponsor: Sandoz

Target Recruit Count: 417

Registration Number: NCT01576341

Locations: 🇺🇦
Sandoz Investigative Site, Zhitomyr, Ukraine

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy